Founded in 1915 in Copenhagen by Hans Lundbeck, H. Lundbeck A/S has developed into a specialized global pharmaceutical company dedicated to brain health, with a long-standing focus on disorders such as depression, schizophrenia, Parkinson’s disease, Alzheimer’s disease, epilepsy, and migraine. Headquartered in Valby, Copenhagen, the company combines research, development, manufacturing, and international commercialization within an integrated platform centered on neuroscience. Lundbeck is present in more than 20 countries, its products are registered in more than 80 countries, and it employs approximately 5,300 people worldwide. In 2025, the company reported revenue of DKK 24.6 billion, reflecting the scale and growing strength of one of Europe’s leading neuroscience-focused pharmaceutical groups.
Updated 2026-03-19